Prophylactically injection of Nicorandil to reduce no-reflow phenomenon during PCI in acute STEMI patients

Protocol of a double-blinded, randomized, placebo-controlled trial

Su An, MB, Huopeng Huang, MB, Huaying Wang, MB, Yunlu Jiang, MB

1. Introduction

An acute ST-elevation myocardial infarction (STEMI) is a very serious type of heart attack and a profoundly life-threatening medical emergency, and percutaneous coronary intervention (PCI) is the preferred strategy. However, in patients undergoing primary PCI, 30% to 40% may suffer the no-reflow phenomenon (NRP), and it could expand the myocardial infarction area and accompanied with high rehospitalization rate and fatality rate. In this study, we try to conduct a double blinded, randomized, placebo-controlled trial to observe whether the prophylactically intracoronary administration of Nicorandil could reduce the occurrence of NRP in STEMI patients undergoing PCI.

Methods: Simple randomization in a 1:1 ratio will be made in blocks of variable size according to a random numbers generated by Excel 2010 to divide the patients to treatment group (Nicorandil) and control group (Saline). The outcomes are the occurrence of NRP, levels of interleukin-6 and HS-CRP, cTnT, and CK-MB before, and every 4 hours following PCI, and major adverse cardiovascular events at day 30. SPSS 23.0 (IBM, Chicago, IL) will be used, and P-value < .05 will be considered statistically significant.

Conclusions: The findings will determine the efficacy of prophylactically intracoronary administration of Nicorandil to reduce the occurrence of NRP during PCI in acute STEMI patients.

Trial registration: OSF Registration number: DOI 10.17605/OSF.IO/QPF3V

Abbreviations: NRP = no-reflow phenomenon, PCI = percutaneous coronary intervention, STEMI = ST-elevation myocardial infarction.

Keywords: Nicorandil, no-reflow phenomenon, percutaneous coronary intervention, ST-elevation myocardial infarction

Abstract

Introduction: An acute ST-elevation myocardial infarction (STEMI) is a very serious type of heart attack and a profoundly life-threatening medical emergency, and percutaneous coronary intervention (PCI) is the preferred strategy. However, in patients undergoing primary PCI, 30% to 40% may suffer the no-reflow phenomenon (NRP), and it could expand the myocardial infarction area and accompanied with high rehospitalization rate and fatality rate. In this study, we try to conduct a double blinded, randomized, placebo-controlled trial to observe whether the prophylactically intracoronary administration of Nicorandil could reduce the occurrence of NRP in STEMI patients undergoing PCI.

Methods: Simple randomization in a 1:1 ratio will be made in blocks of variable size according to a random numbers generated by Excel 2010 to divide the patients to treatment group (Nicorandil) and control group (Saline). The outcomes are the occurrence of NRP, levels of interleukin-6 and HS-CRP, cTnT, and CK-MB before, and every 4 hours following PCI, and major adverse cardiovascular events at day 30. SPSS 23.0 (IBM, Chicago, IL) will be used, and P-value < .05 will be considered statistically significant.

Conclusions: The findings will determine the efficacy of prophylactically intracoronary administration of Nicorandil to reduce the occurrence of NRP during PCI in acute STEMI patients.

Trial registration: OSF Registration number: DOI 10.17605/OSF.IO/QPF3V

Abbreviations: NRP = no-reflow phenomenon, PCI = percutaneous coronary intervention, STEMI = ST-elevation myocardial infarction.

Keywords: Nicorandil, no-reflow phenomenon, percutaneous coronary intervention, ST-elevation myocardial infarction

1. Introduction

An acute ST-elevation myocardial infarction (STEMI) is a very serious type of heart attack and a profoundly life-threatening medical emergency, cause by the occlusion of 1 or more coronary arteries to result in myocardial injury or necrosis. Approximately 500,000 patients suffer STEMI annually,[1] and it is estimated that STEMI comprises 25% to 40% of myocardial infarction presentation.[2] Reperfusion therapy is reasonable for STEMI 12 to 24 hours within the onset. Percutaneous coronary intervention (PCI) is the preferred strategy, and it could rapidly re-canalize the infarct arteries, significantly reduce infarct area, and improve clinical outcome and long-term prognosis.[3,4]

However, in patients undergoing primary PCI, although without obvious dissection, thrombosis, spasm, or severe residual stenosis, 30% to 40% of patients may suffer the no-reflow phenomenon (NRP)[5,6]: after the recanalization of infarcted arteries, coronary blood flow to the ischemic tissue may still be impeded and the myocardial cell perfusion cannot be maintained. NRP is one of the common serious complications after PCI in STEMI patients, and it could expand the myocardial infarction area and accompanied with high rehospitalization rate and fatality rate.[7–9]

Many efforts have been made to prevent or reduce the occurrence of NRP, such as the administration of statins and Nicorandil.[10–12] Nicorandil is an ATP-sensitive K+ opener, and it could dilate coronary artery to increase blood flow. Nicorandil has been administered in treating NRP in patients after PCI in some studies, and it may improve the symptoms of no-reflow in patient.[13] However, there is still a lack of high quality

Received: 17 March 2021 / Accepted: 24 March 2021
http://dx.doi.org/10.1097/MD.0000000000025500
randomized controlled trial to show the efficacy and safety of Nicorandil in preventing NRP during PCI in acute STEMI patients. In this study, we try to conduct a double blinded, randomized, placebo-controlled trial to observe whether the prophylactically intracoronary administration of Nicorandil could reduce the occurrence of NRP in STEMI patients undergoing PCI.

2. Methods

2.1. Study design

We will perform the double blinded, randomized, placebo-controlled trial (registration number: DOI 10.17605/OSF.IO/QPF3V) in Chongqing Dazu District People’s Hospital from May 1st, 2021 to April 31st, 2022. The protocol has been approved by the Health Research Ethics Board in the hospital. We will carry out the procedure in accordance with the Declaration of Helsinki. The flow of patients screening, randomization, and follow-up are presented in Figure 1.

2.2. Participants studied

Patients with sustained acute STEMI and suitable for PCI in hospital will be screened. Patients meeting the following criteria will be included:

1. aging from 18 to 85 years old;
2. diagnosis of acute STEMI within 12 hours;
3. total occlusion of the infarcted artery;
4. blood pressure less than 90/60 mm Hg.

Patients with left bundle-branch block, kidney dysfunction, and histories of myocardial infarction, PCI, coronary artery bypass grafting will be excluded. Before randomization, all patients or authorized persons will sign a written informed consent, and they can freely choose whether to continue the trial at any time.

2.3. Randomization and blinding

Simple randomization in a 1:1 ratio will be made in blocks of variable size according to a random numbers generated by Excel 2010 to divided the patients to treatment group (intracoronary...
injection of 2 mg Nicorandil) and control group (intracoronary injection of 2 mL Saline). The attending physician, patients, outcome evaluators, and statistical analysts will be blinded to the allocation. To maintain blinding, Nicorandil and Saline are in the same package and appearance.

2.4. Interventions
All patients in both groups will take antiplatelet drugs including 300 mg Aspirin (Bayer, Germany) and 600 mg Clopidogrel (Sanofi [Hangzhou] Pharmaceutical Co., Ltd, Hangzhou, China), and Heparin (70U/kg) will be injected through the artery sheath tube before PCI.

In the treatment group, 2 mg Nicorandil (Beijing Sihuan Kebao Pharmaceutical Co. Ltd, Beijing, China) will be injected 2 mm distal to the site of the occlusion in the coronary artery in the thrombus-aspiration catheter. Angiography will be repeated 5 minutes later to determine whether to repeatedly administer 2 mg Nicorandil. The total dose of Nicorandil should not exceed 6 mg in any patients.

In the control group, 2 mL Saline (Tianjin Barence Biotechnology Co., Ltd, Tianjin, China) will be injected 2 mm distal to the site of the occlusion in the coronary artery in the thrombus-aspiration catheter. Angiography will be repeated 5 minutes later to determine whether to repeatedly administer 2 mL Saline. The total dose of Nicorandil should not exceed 6 mL in any patient.

2.5. Outcome measures
The primary outcome is the occurrence of NRP defined as follows: thrombolysis in myocardial infarction flow grade less than 2 without dissection, spasm, or significant residual stenosis, at the end of interventional procedure, and a decrease of less than 50% of the basal elevation of ST segment at 90 minutes after reperfusion with PCI.

The secondary outcomes are levels of interleukin-6 and hs-CRP, cTnT, and CK-MB before, and every 4 hours following PCI, and major adverse cardiovascular events (postinfarction angina, reinfarction, heart failure, arrhythmias, cardiogenic shock, and cardiovascular death) at day 30.

2.6. Sample size
As previous literature reports, the occurrence of NRP was over 30%.[5,6] We preliminarily found that Nicorandil could reduce the occurrence to 15%, and taking α = 5%, 1-β = 80% with a 2-sided test, 118 cases will be calculated in each group. Considering a potential dropout of 20% in the 30-day-follow-up, 280 cases will be needed in total.

2.7. Statistical methods
Data with a normal distribution will be expressed as mean ± standard deviation, and categorical data as percentages. Student t test, Wilcoxon rank-sum test, Mann–Whitney U test, χ² test, or Fisher exact test will be applied accordingly. SPSS 23.0 (IBM, Chicago, IL) will be used, and P < .05 will be considered statistically significant.

3. Discussion
Currently, PCI is considered as one of the most effective measures for the treatment of acute STEMI.[4,14,15] Within 12 hours of the onset of STEMI, PCI could rapidly re-canalize the infarcted related arteries, restore myocardial perfusion, and significantly reduce infarct size and mortality in acute STEMI patients. However, coronary angiography studies showed that a large number of patients suffer from NRP, the inadequate reperfusion of the myocardium without evidence of coronary artery obstruction after PCI.[5,6] The phenomenon was thought to be associated with endothelial damage, inflammation, vascular spasm, platelet activation and aggregation, and thromboembolism.[16,17] The NRP can be a marker of myocardial injury, ischemia, infarction, and a predictor of higher incidence of major adverse cardiovascular events. It could seriously affect the prognosis of STEMI patients and increase mortality, which makes it in great significance to prevent and reduce the occurrence of NRP in STEMI patients during PCI.

It has been reported that Nicorandil could improve endothelial inflammation, fibrinolytic ability, and stabilize plaques,[18–20] and the prophylactic application of Nicorandil before PCI may have the potential to reduce the occurrence of NRP to improve prognosis for acute STEMI. Therefore, to provide higher clinical evidence, we try to conduct a double blinded, randomized, placebo-controlled trial to determine the efficacy of prophylactically intracoronary administration of Nicorandil to reduce the occurrence of NRP during PCI in acute STEMI patients.

Indeed, several limitations need to be addressed. First, there might be bias due to the single-centered study. Second, quantitative analyses for accurately evaluating cardiac function are also needed, such as SPECT and cardiac magnetic resonance.

Author contributions
Data curation: Su An, Huopeng Huang.
Funding acquisition: Yunlu Jiang.
Investigation: Yunlu Jiang.
Resources: Su An, Huopeng Huang.
Software: Huopeng Huang, Huaying Wang.
Supervision: Huaying Wang.
Writing – original draft: Su An, Huopeng Huang.
Writing – review & editing: Su An, Yunlu Jiang.

References
[1] Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction–executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). J Am Coll Cardiol 2004;44:671–719.
[2] O’gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;127:529–55.
[3] Zeitouni M, Akin I, Desch S, et al. Clinical outcomes according to ECG presentations in infarct-related cardiogenic shock in the culprit lesion only PCI vs multivessel PCI in cardiogenic shock trial. Chest 2020;10.1016/j.chest.2020.10.089.
[4] Alyamani M, Campbell S, Navarese E, et al. Safety and efficacy of intracoronary thrombolysis as adjunctive therapy to primary PCI in STEMI: a systematic review and meta-analysis. Can J Cardiol 2021;37:339–46.
[5] Chen C, Fu X, Li W, et al. Intracoronary administration of anisodamine and nicorandil in individuals undergoing primary percutaneous coronary intervention for acute inferior myocardial infarction: a randomized factorial trial. Exp Ther Med 2015;10:1039–45.
[6] Celik T, Balta S, Ozturk C, et al. Predictors of no-reflow phenomenon in young patients with acute ST-segment elevation myocardial infarction.
undergoing primary percutaneous coronary intervention. Angiology 2016;67:683–9.
[7] Papapostolou S, Andrianopoulos N, Duffy SJ, et al. Long-term clinical outcomes of transient and persistent no-reflow following percutaneous coronary intervention (PCI): a multicentre Australian registry. EuroIntervention 2018;14:185–93.
[8] Schram HCF, Hemradj VV, Hermanides RS, et al. Coronary artery ectasia, an independent predictor of no-reflow after primary PCI for ST-elevation myocardial infarction. Int J Cardiol 2018;265:12–7.
[9] Sumaya W, Parker WAE, Fretwell R, et al. Pharmacodynamic effects of a 6-hour regimen of enoxaparin in patients undergoing primary percutaneous coronary intervention (PENNY PCI study). Thromb Haemost 2018;118:1250–6.
[10] Garcia-Mendez RC, Almeida-Gutierrez E, Serrano-Cuevas L, et al. Reduction of no reflow with a loading dose of atorvastatin before primary angioplasty in patients with acute ST myocardial infarction. Arch Med Res 2018;49:620–9.
[11] Qi Q, Niu J, Chen T, et al. Intracoronary nicorandil and the prevention of the no-reflow phenomenon during primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction. Med Sci Monit 2018;24:2767–76.
[12] Feng C, Liu Y, Wang L, et al. Effects of early intracoronary administration of nicorandil during percutaneous coronary intervention in patients with acute myocardial infarction. Heart Lung Circ 2019;28:855–65.
[13] Kobatake R, Sato T, Fujiwara Y, et al. Comparison of the effects of nitroprusside versus nicorandil on the slow/no-reflow phenomenon during coronary interventions for acute myocardial infarction. Heart Vessels 2011;26:379–84.
[14] Zeymer U, Leva O, Hublouser SH, et al. Dual antithrombotic therapy with dabigatran in patients with atrial fibrillation after percutaneous coronary intervention for ST elevation myocardial infarction: results from the randomised RE-DUAL PCI trial. EuroIntervention 2020; doi:10.4244/EIJ-D-20-00799. Epub ahead of print.
[15] Kim YH, Her AY, Jeong MH, et al. Two-year clinical outcomes between prediabetic and diabetic patients with STEMI and multivessel disease who underwent successful PCI using drug-eluting stents. Angiology 2021;72:50–61.
[16] Movahed MR, Butman SM. The pathogenesis and treatment of no-reflow occurring during percutaneous coronary intervention. Cardiovasc Revasc Med 2008;9:56–61.
[17] Bolayir HA, Gunes H, Kivrak T, et al. The role of SCUBE1 in the pathogenesis of no-reflow phenomenon presenting with ST segment elevation myocardial infarction. Anatol J Cardiol 2017;18:122–7.
[18] Hu K, Wang X, Hu H, et al. Intracoronary application of nicorandil regulates the inflammatory response induced by percutaneous coronary intervention. J Cell Mol Med 2020;24:4863–70.
[19] Kseibati MO, Shehatou GSG, Sharawy MH, et al. Nicorandil ameliorates bleomycin-induced pulmonary fibrosis in rats through modulating eNOS, iNOS, TXNIP and HIF-1alpha levels. Life Sci 2020;246:117423.
[20] Lenz M, Kaun C, Krychtiuk KA, et al. Effects of nicorandil on inflammation, apoptosis and atherosclerotic plaque progression. Biomedicines 2021;9:120.